This study aims to develop a point-of-care (POC) electrochemical immunosensor to monitor the anticoagulant activity of direct oral anticoagulants (DOACs) by detecting and distinguishing between the inactive (FX) and active (FXa) forms of Factor X. DOACs have transformed the management of thromboembolic disorders by selectively inhibiting FXa. Common monitoring methods are either insufficiently sensitive to DOAC levels or not widely accessible. This study demonstrates the development of a graphene-based electrochemical immunosensor modified by gold nanostructures and functionalized with anti-FX antibodies. Electrode modifications were characterized by cyclic voltammetry (CV), differential pulse voltammetry (DPV), and field-emission scanning electron microscopy (FESEM), showing enhanced electron transfer and increased current peaks (I pc: −241.4 μA, I pa: 244.6 μA). The sensor distinguished synthetic blood samples with FXa from negative and positive for FX (only 20 μL sample) via DPV peak area analysis (cutoff of 10.65 and 12.42 μA·V). An enzyme-linked immunosorbent assay was performed to verify antigen–antibody interactions, demonstrating less sensitivity to differentiate FX from FXa than DPV. Structural bioinformatics confirmed the loss of a 51-amino acid activation peptide in FXa, reducing molecular volume and likely affecting electrochemical response. In silico docking of seven nonpathogenic F10 variants in DOAC binding regions showed minimal impact on drug binding, supporting sensor applicability across genetic variations. This work demonstrates a sensitive, selective immunosensor for discriminating coagulation factor activation states, supporting point-of-care anticoagulant therapy monitoring.
Phenylalanine (Phe) accumulation in blood is a hallmark of phenylketonuria (PKU), a metabolic disorder that requires early diagnosis and lifelong monitoring to prevent irreversible neurological damage. Conventional analytical methods rely on centralized laboratory infrastructure, limiting their use in decentralized and point-of-care (POC) settings. Here, we report an enzymatic electrochemical biosensor based on screen-printed carbon–graphene electrodes modified with gold nanoparticles (AuNPs) and functionalized with phenylalanine dehydrogenase (PheDH). The biosensor exhibited a linear response across physiological and pathological Phe concentrations, with a sensitivity of 13.6 μC (mg dL–1)–1 and a limit of detection of 0.12 mg dL–1. Michaelis–Menten analysis yielded an apparent Km of 1.31 mg dL–1 and a maximum charge (Qmax) of 316 μC, indicating high affinity between the immobilized enzyme and Phe. The platform also enabled quantitative detection in spiked biological matrices, demonstrating its applicability to clinically relevant samples. Bioinformatic and structural analyses revealed that AuNPs promote a favorable enzyme orientation that enhances substrate accessibility and electron transfer. By integrating electrochemical measurements with molecular-level modeling, this work establishes a rational strategy for designing high-performance enzymatic biosensors. The compatibility of the platform with portable electrochemical instrumentation highlights its translational potential for decentralized and self-monitoring applications in PKU management, although further validation with larger clinical sample sets and long-term stability studies is required.
Background: The emergence of SARS-CoV-2 variants is a current public health concern possibly impacting COVID-19 disease diagnosis, transmission patterns and vaccine effectiveness. Objectives: To describe the SARS-CoV-2 lineages circulating early pandemic among samples with S gene dropout and characterize a novel mutation in receptor-binding domain (RBD) of viral spike protein. Study design: Adults and children older than 2 months with signs and symptoms of COVID-19 were prospectively enrolled from May to October 2020 in Porto Alegre, Brazil. All participants performed RT-PCR assays for diagnosing SARS-CoV-2, samples with S gene dropout and Ct < 30 (cycle threshold) were submitted to whole genome sequencing (WGS), and homology modeling and physicochemical properties analysis were performed. Results: 484/1,557 participants tested positive for SARS-CoV-2. The S gene dropout was detected in 7.4% (36/484) as early as May, and a peak was observed in early August. WGS was performed in 8 samples. The B.1.1.28, B.1.91 and B.1.1.33 lineages were circulating in early pandemic. The RBD novel mutation (Y380Q) was found in one sample occurring simultaneously with C379W and V395A, and the B.1.91 lineage in the spike protein. Conclusion: Mutations in the SARS-CoV-2 spike region were detected early in the COVID-19 pandemic in Southern Brazil, regarding the B.1.1.28, B.1.91 and B.1.1.33 lineages identified. The novel mutation (Y380Q) with C379W, modifies important RBD properties, which may interfere with the binding of neutralizing antibodies (CR3022, EY6A, H014, S304). Highlights: Characterization of novel mutation (Y380Q) in RBD of SARS-CoV-2 spike protein The Y380Q and C379W modify important properties in the SARS-CoV-2 RBD region The RBD mutations may interfere with the binding of neutralizing antibodies The B.1.1.28, B.1.91 and B.1.1.33 lineages were circulating in early pandemic